|
Epocrates Inc. Announces Strategic
Investment by Goldman Sachs
Hudson Street Division to Offer Company’s Services
SAN MATEO, CALIF., January 7, 2008 - Epocrates, Inc., developer
of clinical solutions for healthcare professionals, announced
today that Goldman Sachs (NYSE: GS) has made a strategic
investment in the company. The companies also entered into an
agreement to co-market Epocrates’ market research services.
“As a leading developer of clinical research tools, Epocrates
has emerged as one of the most recognized healthcare technology
companies among physicians, and we are pleased to introduce its
services to our clients," said Michael Sanders, Managing
Director, Goldman, Sachs & Co., and head of Hudson Street.
More than 500,000 healthcare professionals use Epocrates’ mobile
or web-based products at the point of care. The company’s
software solutions feature drug, disease and diagnostic decision
support tools that help physicians improve the quality of
patient care and increase productivity. In addition, Epocrates
recruits clinicians to participate in market research studies.
Study topics range from assessing interest in new pharmaceutical
compounds to understanding current disease treatment protocols.
“We have the largest, verified market research panel in the
nation, including more than 145,000 opted-in physicians. We are
looking forward to working with Hudson Street to serve the
research needs of Goldman Sachs’ clients,” said Kirk Loevner,
chairman and chief executive officer of Epocrates.
As part of the agreement, Hudson Street, a Goldman Sachs
business, will co-market Epocrates’ market research products and
services to its institutional clients in the financial sector.
About Hudson Street Services
Hudson Street Services, a Goldman Sachs business, offers
investment professionals access to a select platform of unique
content and tools that can be integrated into their investment
process. Collectively, Hudson Street Services offer a more
flexible, more efficient way for clients to access critical
information and ultimately make better investment decisions.
Contact
Erica Sniad Morgenstern
Epocrates Public Relations
PHONE: (650) 227-6907
E-MAIL: pr@epocrates.com
WEB: www.epocrates.com
|
